<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231565</url>
  </required_header>
  <id_info>
    <org_study_id>PL10</org_study_id>
    <nct_id>NCT04231565</nct_id>
  </id_info>
  <brief_title>Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.</brief_title>
  <acronym>ALTHBV</acronym>
  <official_title>Study on Therapeutic Effects and Safety of Nucleoside (Acid) Analogues Treatment in Patients With Chronic Hepatitis B With Normal Alanine Aminotransferase and Positive Hepatitis B Virus DNA: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the clinical efficacy and safety of Nucleoside (acid) analogues&#xD;
      treatment in patients with normal Alanine Aminotransferase and positive Hepatitis B virus&#xD;
      DNA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis b virus infection has always been a global public health problem that endangers&#xD;
      national health. Current clinical guidelines do not recommend antiviral therapy for people&#xD;
      with positive hepatitis b-DNA and normal Alanine Aminotransferase, but studies have found&#xD;
      that viral replication is associated with an increased risk of cirrhosis and liver tumors.&#xD;
      Nucleoside (acid) analogues can effectively inhibit viral reverse transcriptase, reduce HBV&#xD;
      viral load in the blood, thereby reducing secondary inflammation, and contribute to liver&#xD;
      cell regeneration and disease recovery. And its side effect is small, adverse reaction rate&#xD;
      is low, use safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hepatitis b s antigen loss rate</measure>
    <time_frame>144 week</time_frame>
    <description>Hepatitis b s antigen become negative and quantitative analysis below the upper limit of test value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hepatitis b e antigen loss rate</measure>
    <time_frame>0 week,12 week,24 week,36 week,48 week,72 week,96 week,120 week,144 week</time_frame>
    <description>Hepatitis b e antigen would be tested to know the ratio of patients with negative hepatitis B e antigen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatitis b virus(HBV) DNA undetectable rate</measure>
    <time_frame>0 week,12 week,24 week,36 week,48 week,72 week,96 week,120 week,144 week</time_frame>
    <description>Hepatitis b virus DNA would not be detected if it below the upper limit of test value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatitis b virus(HBV) RNA undetectable rate</measure>
    <time_frame>0 week,12 week,24 week,36 week,48 week,72 week,96 week,120 week,144 week</time_frame>
    <description>Hepatitis b virus RNA would not be detected if it below the upper limit of test value</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatitis B Virus</condition>
  <arm_group>
    <arm_group_label>TAF group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients would receive treatment of oral Tenofovir alafenamide Fumarate(TAF) 25 mg once per day from baseline to life-long.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>50 patients would not receive treatment from baseline to life-long.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir alafenamide Fumarate</intervention_name>
    <description>Patients would receive treatment of oral Tenofovir alafenamide Fumarate（TAF）once per day.</description>
    <arm_group_label>TAF group</arm_group_label>
    <other_name>Vemlidy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive hepatitis b surface antigen and hepatitis b antibody &gt; 0.5 year;&#xD;
&#xD;
          -  Age from 18 to 65 years old;&#xD;
&#xD;
          -  Serum Alanine Aminotransferase(ALT) ≤1×ULN at least 12 weeks;&#xD;
&#xD;
          -  Positive Hepatitis b virus(HBV);&#xD;
&#xD;
          -  Do not receive nucleotide/nucleoside analogues or interferon treatment in the past&#xD;
             half year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other active liver diseases;&#xD;
&#xD;
          -  Hepatocellular carcinoma or other malignancy;&#xD;
&#xD;
          -  Pregnancy or lactation;&#xD;
&#xD;
          -  Human immunodeficiency virus infection or congenital immune deficiency diseases;&#xD;
             5.Severe diabetes, autoimmune diseases; 6.Other important organ dysfunctions; 7.Using&#xD;
             glucocorticoid; 8.Patients can not follow-up; 9.Investigator considering&#xD;
             inappropriate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang Peng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lu Wang, Doctor</last_name>
    <phone>+8618814369232</phone>
    <email>wanglu910525@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Peng, Doctor</last_name>
    <phone>+8613533978874</phone>
    <email>pzp33@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Peng, Doctor</last_name>
      <phone>+8613533978874</phone>
      <email>pzp33@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Liang Peng</investigator_full_name>
    <investigator_title>Professer</investigator_title>
  </responsible_party>
  <keyword>hepatitis B virus</keyword>
  <keyword>nucleoside</keyword>
  <keyword>nucleotide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underline the results reported in this article (text, tables, figures and appendices) will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following the article publication.</ipd_time_frame>
    <ipd_access_criteria>Proposals should be directed to xxx@yyy. To gain access, data requestors need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

